(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 2.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.83%.
Moderna's revenue in 2025 is $3,078,000,000.On average, 10 Wall Street analysts forecast MRNA's revenue for 2025 to be $737,836,844,304, with the lowest MRNA revenue forecast at $624,473,009,985, and the highest MRNA revenue forecast at $853,329,723,052. On average, 10 Wall Street analysts forecast MRNA's revenue for 2026 to be $976,338,844,547, with the lowest MRNA revenue forecast at $585,863,069,379, and the highest MRNA revenue forecast at $2,204,720,443,041.
In 2027, MRNA is forecast to generate $1,309,175,566,354 in revenue, with the lowest revenue forecast at $906,012,289,389 and the highest revenue forecast at $3,086,375,172,403.